MP Healthcare Venture Management
Home About Us Portfolio News Contact
HomeAbout UsPortfolioNewsContact
MP Healthcare Venture Management
Thrasos Secures $35 Million to Fund THR-184 Phase 2 Clinical Program for Treatment of Acute Kidney Injury.
Guest UserOctober 25, 2012
Facebook0 Twitter LinkedIn0 Reddit 0 Likes
Previous

Genkyotex's NOX Inhibitor GKT137831 Phase I Data Presented at Kidney Week 2012.

Guest UserNovember 2, 2012
Next

Covagen enters into a strategic research collaboration and license agreement with Mitsubishi Tanabe for the development of bispecific FynomAbs.

Guest UserOctober 17, 2012

© 2010-2025 MP Healthcare Venture Management, Inc.
All Rights Reserved.

Privacy Policy | Terms of Use

About UsPortfolioNews Contact